Journals / Abant Tıp Dergisi / 2025 / Cilt: 14 Sayı: 3

Structural Analysis and Docking Studies of FK506-Binding Protein 1A (FKBP1A)

Hasan Demirci(KOÇ ÜNİVERSİTESİ, FEN FAKÜLTESİ)0000-0002-9135-5397
Pages
130–159
Publication Date
2025-12-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The combination of our high-resolution X-ray crystallographic and docking-based virtual screening results reveal alternative binding pockets that could serve as new targets for therapeutic modulation of FKBP1A function.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: FK506-binding protein 1A (FKBP1A) is a peptidyl-prolyl cis–trans isomerase involved in protein folding, signal transduction, and calcium homeostasis.
📊
Key Findings & Data:This work aims to elucidate the structural features of FKBP1A at high resolution and explore potential ligand interactions through molecular docking across three distinct putative binding pockets.
💡
Conclusion & Impact:The combination of our high-resolution X-ray crystallographic and docking-based virtual screening results reveal alternative binding pockets that could serve as new targets for therapeutic modulation of FKBP1A function.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:FKBP1A · Structural Biology · X-ray Crystallography

Abstract

Objective: FK506-binding protein 1A (FKBP1A) is a peptidyl-prolyl cis–trans isomerase involved in protein folding, signal transduction, and calcium homeostasis. Despite its well-studied biochemical role, structural insights into its ligand-binding diversity remain limited. This work aims to elucidate the structural features of FKBP1A at high resolution and explore potential ligand interactions through molecular docking across three distinct putative binding pockets. Materials and Methods: The crystal structure of human FKBP1A was determined at 1.05 Å resolution, allowing detailed visualization of side-chain conformations, hydrogen-bonding networks, and solvent organization at atomic resolution. Molecular docking was performed using the FDA-approved compound library from DrugBank with Molegro Virtual Docker. Three potential binding pockets—one at the inter-chain region and two mirroring pockets at Chain A and Chain B—were screened independently. The top-ranked compounds were evaluated based on rerank scores and interaction profiles. Results: The high-resolution structure revealed well-defined active-site geometry and multiple hydration states, supporting the catalytic flexibility of FKBP1A. Docking analyses identified several high-affinity ligands with distinct binding preferences across the three sites. The canonical active site favored classical FKBP inhibitors, while the secondary and interface pockets accommodated chemically diverse compounds forming novel hydrogen-bond and π–π stacking interactions. Conclusion: This study provides an atomic-level view of FKBP1A and expands the understanding of its ligand-binding landscape. The combination of our high-resolution X-ray crystallographic and docking-based virtual screening results reveal alternative binding pockets that could serve as new targets for therapeutic modulation of FKBP1A function.

🔖

Cite This Article

Guven, O., Demirci, H. (2025). Structural Analysis and Docking Studies of FK506-Binding Protein 1A (FKBP1A). Abant Tıp Dergisi, Cilt: 14 Sayı: 3, 130–159. https://doi.org/10.47493/abantmedj.1810545

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (42)

  1. Tong M, Jiang Y. FK506-binding proteins and their diverse functions. Curr Mol Pharmacol. 2015;9(1):48–65.
  2. Kasahara K. Physiological function of FKBP12, a primary target of rapamycin/FK506: a newly identified role in transcription of ribosomal protein genes in yeast. Curr Genet. 2021;67(3):383–8.
  3. Gonano LA, Jones PP. FK506-binding proteins 12 and 12.6 (FKBPs) as regulators of cardiac ryanodine receptors: insights from new functional and structural knowledge. Channels (Austin). 2017;11(5):415–25.
  4. Stockwell BR, Schreiber SL. TGF-β signaling with small-molecule FKBP12 antagonists that bind myristoylated FKBP12–TGF-β type I receptor fusion proteins. Chem Biol. 1998;5(7):385–95.
  5. Quist-Løkken I, Andersson-Rusch C, Kastnes MH, Kolos JM, Jatzlau J, Hella H, et al. FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells. Cell Commun Signal. 2023;21(1):1–16.
  6. Li Z, Cui Y, Duan Q, Zhang J, Shao D, Cao X, et al. The prognostic significance of FKBP1A and its related immune infiltration in liver hepatocellular carcinoma. Int J Mol Sci. 2022;23(21):12869.
  7. Cai S, Chen Z, Tang H, Meng S, Tao L, Wang Q. Upregulated FKBP1A suppresses glioblastoma cell growth via apoptosis pathway. Int J Mol Sci. 2022;23(23):15247.
  8. Mathea S, Li S, Schierhorn A, Jahreis G, Schiene-Fischer C. Suppression of EGFR autophosphorylation by FKBP12. Biochemistry. 2011;50(50):10844–50.
  9. Caminati G, Procacci P. Mounting evidence of FKBP12 implication in neurodegeneration. Neural Regen Res. 2020;15(12):2195–6.
  10. Chattopadhaya S, Harikishore A, Yoon HS. Role of FK506-binding proteins in neurodegenerative disorders. Curr Med Chem. 2011;18(35):5380–97.
  11. Avramut M, Achim CL. Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav. 2002;77(4–5):463–8.
  12. Koren J, Jinwal UK, Davey Z, Kiray J, Arulselvam K, Dickey CA. Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies. Mol Neurobiol. 2011;44(1):65–70.
  13. Romano S, D’Angelillo A, Romano MF. Pleiotropic roles in cancer biology for multifaceted proteins FKBPs. Biochim Biophys Acta. 2015;1850(10):2061–8.
  14. Solassol J, Mange A, Maudelonde T. FKBP family proteins as promising new biomarkers for cancer. Curr Opin Pharmacol. 2011;11(4):320–5.
  15. Theuerkorn M, Fischer G, Schiene-Fischer C. Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol. 2011;11(4):281–7.
  16. Romano S, Di Pace A, Sorrentino A, Bisogni R, Sivero L, Romano MF. FK506-binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem. 2010;10(9):651–6.
  17. Yao YL, Liang YC, Huang HH, Yang WM. FKBPs in chromatin modification and cancer. Curr Opin Pharmacol. 2011;11(4):301–7.
  18. Xing M, Wang J, Yang Q, Wang Y, Li J, Xiong J, et al. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer. Cancer Chemother Pharmacol. 2019;84(4):861–72.
  19. Ertem FB, Guven O, Buyukdag C, Gocenler O, Ayan E, Yuksel B, et al. Protocol for structure determination of SARS-CoV-2 main protease at near-physiological temperature by serial femtosecond crystallography. STAR Protoc. 2022;3(1):101158.
  20. Garman EF, Owen RL. Cryocooling and radiation damage in macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2006;62(Pt 1):32–47.
  21. Atalay N, Akcan EK, Gül M, Ayan E, Destan E, Ertem FB, et al. Cryogenic X-ray crystallographic studies of biomacromolecules at Turkish Light Source “Turkish DeLight.” Turk J Biol. 2023;47(1):22–33.
  22. Meyer M. CrysalisPro 43: synergy in X-ray and electron diffraction. Acta Crystallogr A Found Adv. 2023;79(Suppl a2):C739.
  23. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–74.
  24. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):213–21.
  25. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126–32.
  26. Bitencourt-Ferreira G, de Azevedo WF Jr. Molegro Virtual Docker for docking. Methods Mol Biol. 2019;2053:149–67.
  27. Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265–75.
  28. Hausch F. FKBPs and their role in neuronal signaling. Biochim Biophys Acta. 2015;1850(10):2035–40.
  29. Blair LJ, Baker JD, Sabbagh JJ, Dickey CA. The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. J Neurochem. 2015;133(1):1–13.
  30. Gant JC, Blalock EM, Chen KC, Kadish I, Porter NM, Norris CM, et al. FK506-binding protein 1b/12.6: a key to aging-related hippocampal Ca2+ dysregulation? Eur J Pharmacol. 2014;739:74–82.
  31. Chen YG, Liu F, Massagué J. Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J. 1997;16(13):3866–77.
  32. Honjo Y, Ayaki T, Horibe T, Ito H, Takahashi R, Kawakami K. FKBP12-immunopositive inclusions in patients with α-synucleinopathies. Brain Res. 2018;1680:39–45.
  33. Cao W, Konsolaki M. FKBP immunophilins and Alzheimer’s disease: a chaperoned affair. J Biosci. 2011;36(3):493–8.
  34. Gerard M, Deleersnijder A, Demeulemeester J, Debyser Z, Baekelandt V. Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration. Mol Neurobiol. 2011;44(1):13–27.
  35. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin–receptor complex. Nature. 1994;369(6483):756–8.
  36. Zissimopoulos S, Seifan S, Maxwell C, Williams AJ, Lai FA. Disparities in the association of the ryanodine receptor and the FK506-binding proteins in mammalian heart. J Cell Sci. 2012;125(Pt 7):1759–69.
  37. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structure of FKBP–FK506, an immunophilin–immunosuppressant complex. Science. 1991;252(5007):839–42.
  38. Chaurasia S, De Gonda R. Molecular insights into the stabilization of protein–protein interactions with small molecule: the FKBP12–rapamycin–FRB case study. Chem Phys Lett. 2013;584:68–73.
  39. Liang TT, Zhao Q, He S, Mu FZ, Deng W, Han BN. Modeling analysis of potential target of Dolastatin 16 by computational virtual screening. Chem Pharm Bull (Tokyo). 2018;66(6):602–7.
  40. Nasr AB, Ponnala D, Sagurthi SR, Kattamuri RK, Marri VK, Gudala S, Lakkaraju C, Bandaru S, Nayarisseri A. Molecular docking studies of FKBP12–mTOR inhibitors using binding predictions. Bioinformation. 2015;11(6):307–15.
  41. Kolos JM, Voll AM, Bauder M, Hausch F. FKBP ligands—where we are and where to go? Front Pharmacol. 2018;9:1425.
  42. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12–rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239–42.